Saturday, September 7, 2024
9/7/2024
Project Summary/Abstract: Gliomas are the most common primary brain tumors in adults, a subset of which have mutations in the metabolic gene isocitrate dehydrogenase 1 (IDH1). Cancer-associated IDH1 mutants (the most common of which is IDH1R132H) are neomorphs that produce the oncometabolite 2-hydroxyglutarate [(R)-2HG], which is thought to contribute to glioma formation. Mutant IDH (mIDH) inhibitors that block (R)-2HG production have been recently shown to improve outcomes in lower-grade IDH-mutant glioma patients and are poised to become standard-of- care. However, response to mIDH inhibitors is heterogeneous, and our understanding of how these drugs may work in glioma has been severely limited by a lack of faithful animal models of lower-grade IDH-mutant gliomas. In an effort to better understand these unanswered questions regarding mIDH1 biology, I made a genetically engineered mouse (GEM) model of mIDH1-driven grade 3 astrocytoma that circumvents key limitations of existing models and provides the opportunity to address fundamental unanswered questions regarding mIDH biology in lower-grade gliomas. I leveraged this GEM and other models to show that IDH-mutant gliomas are sensitive to de novo pyrimidine synthesis inhibitors (e.g. dihydroorotate dehydrogenase (DHODH) inhibitors) due to an increased susceptibility of IDH-mutant cells to DNA damage caused by these drugs. However, whether this sensitivity to DNA damage extends to other standard-of-care therapies, and the mechanisms underlying these effects, is not fully understood. My overall objective is to leverage the key advantages of my grade 3 IDH-mutant GEM to address fundamental questions regarding mutant IDH in glioma: I will determine the response of my GEM model to mIDH inhibitors and evaluate molecular signatures of mIDH inhibitor treatment, determine whether mIDH inhibitors and/or DHODH inhibitors alter response to radiation, and identify mechanisms underlying how IDH-mutant gliomas respond to DNA damaging treatments. I am a radiation oncologist with a research background in glioma biology and a long-term goal of directing my own independent laboratory as an academic physician scientist. I aim to focus my research on understanding the mechanisms driving glioma growth, with the goal of harnessing this knowledge to develop novel therapeutic strategies. I am conducting research in the laboratory of Dr. William G. Kaelin, Jr., MD at Dana-Farber Cancer Institute (DFCI), which I will continue during my proposed K08 research. As an Instructor, 80% of my time is spent on research in the Kaelin lab and 20% is on patient care treating patients with glioma tumors. I have assembled an expert Scientific Advisory Committee to help guide my research and career development: (1) Dr. Stephen Elledge, PhD (Harvard Medical School), (2) Dr. Alan D’Andrea, MD, (DFCI), (3) Dr. Bradley Bernstein, MD/PhD (DFCI), and (4) Dr. Samuel McBrayer, PhD (UT Southwestern). My clinical mentors are Dr. Patrick Wen and Dr. Daphne Haas-Kogan, both world leaders in neuro-oncology. My training in this environment will be outstanding preparation to achieve my long-term career goals as an independent investigator.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
